Loading…
Loading…
Vertex Pharmaceuticals Inc
NASDAQ · Stock Profile · Market Cap $114.58B
Current Price
$451.59
-2.36%GoodMoat Value
$344.45
23.7% overvaluedHolds 2.8x more cash than debt — a strong balance sheet.
Net Cash: 3.2B
2.6B
FY24
2.8B
FY24
11.0B
FY24
2.8B
FY25
3.0B
FY25
3.1B
FY25
12.0B
FY25
—
FY24
1.0B
FY24
—
FY24
646M
FY25
1.0B
FY25
1.1B
FY25
4.0B
FY25
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1. Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 15 consecutive years on Science magazine's Top Employers list and one of Fortune’s 100 Best Companies to Work For.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
Massachusetts, USA
Price sits at 58% of its 52-week range.
Blended fair value estimate based on DCF, Graham Number, and earnings-based models.
Run a full DCF analysis with customizable assumptions
Open DCF Calculator →Graham Number, PEG-based, and Earnings-based models
View Fair Value →This stock does not currently pay a dividend.
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1. Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 15 consecutive years on Science magazine's Top Employers list and one of Fortune’s 100 Best Companies to Work For.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
Massachusetts, USA